★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Johnson & Johnson (JNJ) Moat Analysis
Johnson & Johnson
JNJ · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Johnson & Johnson operates Innovative Medicine and MedTech. Innovative Medicine's moat is primarily legal: patents and related exclusivities support pricing until they expire, while STELARA's 55.7% Q2 operational decline shows how quickly biosimilar entry can erode sales. Clinical and regulatory execution are not separate moats because large peers have comparable capabilities. MedTech's clearest barrier is clinician training and workflow friction in procedure-focused categories, especially Orthopaedics, plus moderate brand preference. The planned Orthopaedics separation would remove much of that evidence. J&J completed its $1B Firefly Bio purchase on July 29 and expects a related Q3 research charge. OTTAVA received U.S. market authorization in July, but commercial adoption remains unproved. Payer pressure, government price controls, product competition, litigation, and separation execution remain important risks.
Primary segment
Innovative Medicine
Market structure
Competitive
Market share
—
HHI: —
Coverage
2 segments · 6 tags
Updated 2026-08-23
Segments
Innovative Medicine
Branded prescription pharmaceuticals (biopharma)
Revenue
64.7%
Structure
Competitive
Pricing
moderate
Share
—
Peers
MedTech
Medical devices and procedure-based consumables (cardiovascular, orthopaedics, surgery, vision)
Revenue
35.3%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Moat Claims
Innovative Medicine
Branded prescription pharmaceuticals (biopharma)
Q2 2026 sales were $16.384B of $25.310B segment sales, and segment income before tax was $6.249B of $7.426B. Operating-profit share uses J&J's reported segment income before tax. STELARA biosimilar pressure reduced worldwide Innovative Medicine operational growth by about 7.6 percentage points.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patent and related exclusivities support pricing and share for key medicines; however, loss of exclusivity and patent challenges can rapidly erode sales via generics/biosimilars.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent cliffs / loss of exclusivity on top products, including ongoing STELARA biosimilar launches
- At-risk generic or biosimilar launches after adverse IP outcomes
- Government price-setting/controls and reimbursement pressure
Leading indicators
- Upcoming loss-of-exclusivity dates for top products
- Biosimilar approvals/launches vs key biologics
- Net price trends (gross-to-net) and payer formulary positioning
Counterarguments
- Payers can accelerate switching to lower-cost alternatives once biosimilars/generics are available
- Patent challenges can shorten expected exclusivity windows
MedTech
Medical devices and procedure-based consumables (cardiovascular, orthopaedics, surgery, vision)
Q2 2026 sales were $8.926B of $25.310B segment sales, and segment income before tax was $1.177B of $7.426B. Operating-profit share uses J&J's reported segment income before tax. The planned Orthopaedics separation remains targeted for completion 18-24 months after the October 2025 announcement.
Training Org Change Costs
Demand
Training Org Change Costs
Strength
Durability
Confidence
Evidence
In procedure-driven device categories, especially orthopaedics and trauma, surgeon training, familiarity, and associated hospital workflows and instrumentation create meaningful switching costs. This advantage is concentrated in the Orthopaedics business slated for separation.
Training Org Change Costs moat: definition, examples, and stocks
Erosion risks
- Hospital procurement standardization can force brand switches
- New enabling technologies can reset clinician preferences
- Cost-containment and tendering can shift purchasing toward lowest price
Leading indicators
- Hospital win/loss rates in tenders and IDN/GPO contracts
- Clinician adoption and utilization metrics in key franchises
- Instrument/platform placements and associated procedure volumes
Counterarguments
- Hospitals can mandate switching when total cost savings are large
- Clinical evidence and innovation can move preferences quickly
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Device markets often compete on perceived quality and reputation; J&J highlights reputation and customer service as key competitive factors and owns established brands (e.g., ACUVUE, TECNIS).
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Product recalls or safety concerns damaging brand equity
- Clinical data favoring competitor devices
- Increasing price transparency reducing brand premium
Leading indicators
- Recall frequency and regulatory warning letters
- Clinician satisfaction/NPS (if disclosed) and repurchase rates
- Average selling price trends and mix shifts
Counterarguments
- In commoditized categories, purchasing can be primarily price-driven
- Reputation can be quickly impaired by quality issues
Evidence
loss of patent exclusivity for a product often is followed by a substantial reduction in sales
Directly supports the dependence on IP/exclusivity and the sharp revenue step-down after generic/biosimilar entry.
These rights are essential to the Company's businesses
Positions patents/proprietary rights as essential to the business model.
the Company can lose a major portion of revenues for the referenced product in a very short period of time.
Supports the cliff dynamics that both define and limit durability of the IP moat.
Any switching to a different supplier thus involves retraining of surgeons and other medical staff in the specific new devices.
Regulatory market investigation explicitly describes retraining costs and clinician reluctance to switch in orthopaedic device markets.
Training and education capabilities of the manufacturers are key assets to access the market
Supports training/education as a structural barrier to entry/expansion in relevant MedTech submarkets.
Showing 5 of 7 sources.
Risks & Indicators
Erosion risks
- Patent cliffs / loss of exclusivity on top products, including ongoing STELARA biosimilar launches
- At-risk generic or biosimilar launches after adverse IP outcomes
- Government price-setting/controls and reimbursement pressure
- Hospital procurement standardization can force brand switches
- New enabling technologies can reset clinician preferences
- Cost-containment and tendering can shift purchasing toward lowest price
Leading indicators
- Upcoming loss-of-exclusivity dates for top products
- Biosimilar approvals/launches vs key biologics
- Net price trends (gross-to-net) and payer formulary positioning
- Share of sales from products launched in past 5 years
- Hospital win/loss rates in tenders and IDN/GPO contracts
- Clinician adoption and utilization metrics in key franchises
Research JNJ elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.